Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Short Interest Update

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totaling 9,061 shares, a growth of 60.0% from the August 31st total of 5,662 shares. Based on an average daily trading volume, of 18,160 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.2% of the company’s stock are sold short.

Cryo-Cell International Stock Up 0.7%

Shares of Cryo-Cell International stock traded up $0.03 during trading hours on Friday, hitting $4.08. 27,839 shares of the company’s stock traded hands, compared to its average volume of 12,990. The stock has a 50 day simple moving average of $3.98 and a 200-day simple moving average of $3.67. The company has a market cap of $32.88 million, a PE ratio of -13.60 and a beta of 0.50. Cryo-Cell International has a twelve month low of $2.72 and a twelve month high of $4.90.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share (EPS) for the quarter. The business had revenue of $7.78 million for the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently raised its stake in Cryo-Cell International stock. Susquehanna International Group LLP lifted its stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,064 shares of the company’s stock after buying an additional 4,046 shares during the quarter. Susquehanna International Group LLP owned approximately 0.17% of Cryo-Cell International worth $45,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a biotechnology and healthcare services company focused on the collection, processing, testing and long-term storage of umbilical cord blood and cord tissue. The company provides families with access to private stem cell banking services intended to preserve potentially valuable biological material for future medical use.

Its services generally include coordinating the collection of cord blood and tissue at birth, transporting specimens to its processing facilities, isolating and cryopreserving stem cells, and maintaining the stored materials under controlled conditions.